Vesalio announces the US commercialisation of pVasc thrombectomy system for non-surgically removing peripheral occlusions.
A recent press release outlined that pVasc targets the full range of emboli from soft acute clots to fibrin-rich, calcified ones. The company states that their Drop Zone technology traps, retains and securely removes thrombus to restore flow in patients suffering from acute limb ischaemia and other conditions related to peripheral artery disease (PAD).
“Given the complicated health history of patients with acute limb ischaemia, physicians often face the challenge of delivering devices through highly diseased arteries and working in small, stenotic vessels,” noted Frank Arko (Sanger Heart and Vascular Institute, Charlotte, USA). He adds that “pVasc has a low profile and excellent deliverability, making it an especially valuable tool when access is difficult or when working in arteries below the knee.”
“I have achieved highly positive results with pVasc in challenging cases that range from organised emboli in the tibialis, to emboli in the brachial and distal ulnar artery,” said Nick Abedi (Fayette Surgical Associates, Lexington, USA). “pVasc has helped my patients avoid open surgery on multiple occasions, becoming an invaluable tool in my practice.”
pVasc is indicated for arteries from 2–6mm in diameter, typically located below the knee, in the femoropopliteal, the mesenteric, the upper extremities, and a few other locations. Comprised of a self-expanding nitinol structure on a pusher wire, pVasc provides a versatile tool with no need for capital equipment, the company states.
“PAD is a common disease that can lead to devastating consequences. With the pVasc thrombectomy system, physicians now have access to a critical tool to help their patients,” stated Vesalio chief executive officer Steve Rybka. “We received extremely encouraging early feedback on pVasc’s ease of use and efficacy in cases with challenging clots. At Vesalio, we remain steadfast in our commitment to provide innovative technologies to physicians treating vascular occlusions.”
